The New Brain Institute, a prominent mental health clinic, is excited to announce the incorporation of Deep Transcranial Magnetic Stimulation (TMS) into its innovative suite of treatments for depression. TMS, a non-invasive procedure, utilizes magnetic fields to stimulate nerve cells in the brain, effectively alleviating symptoms of depression. This cutting-edge therapy targets specific brain regions associated with decreased activity in individuals experiencing depression and serves as a viable option when other treatment methods have proven ineffective.

In addition to offering TMS treatment for depression, The New Brain Institute specializes in addressing various mental health challenges such as anxiety, cognitive enhancement, dementia, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), smoking cessation, as well as ketamine therapy and medication management. Dr. Jack's remarkable expertise and dedication to patient care have positioned The New Brain Institute at the forefront of mental health services.

Patients who have undergone Deep TMS at The New Brain Institute have reported remarkable improvements in their overall well-being. Several patients have even provided heartfelt video testimonials, sharing their personal success stories and expressing gratitude for the institute's commitment to their recovery.

To enhance accessibility, The New Brain Institute accepts most major insurance carriers and offers complimentary insurance verification to prospective patients, aiming to make mental health treatment as attainable as possible. Their well-appointed facility in Beverly Hills, California, provides a comfortable and supportive environment for patients seeking transformative treatment options.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

New Brain Institute, a leading facility dedicated to mental health treatment, is proud to introduce SPRAVATO™, an FDA-approved ketamine therapy for treatment-resistant depression (TRD) in adults. SPRAVATO™ is a nasal spray administered in the institute's state-of-the-art treatment center, providing hope to patients who have not found relief from traditional antidepressant medications.

New Brain Institute proudly announces the introduction of SPRAVATO™, a ketamine-based therapy, offering a novel approach to treating depression. This treatment is especially significant for patients who have not found relief with traditional antidepressants.

SPRAVATO™ is administered under strict medical supervision. The initial phase includes treatments twice a week for four weeks, followed by weekly sessions for one month. Depending on individual responses, the frequency may be adjusted to once every one or two weeks.

This ketamine treatment has demonstrated superior efficacy compared to traditional pharmaceuticals, positioning it as a promising solution for those struggling with depression. With minimal side effects, SPRAVATO™ is emerging as a game-changer in mental health care.

Each treatment session at the New Brain Institute involves extensive monitoring by healthcare professionals in a comfortable setting, ensuring patient safety and well-being. Patients are advised to avoid driving or operating machinery until the following day. The institute also provides various insurance options to make this transformative therapy more accessible.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Unlike traditional pharmaceuticals, SPRAVATO™ has been proven to be significantly more effective in treating depression with minimal side effects. Patients are administered the nasal spray under the supervision of a doctor in a comfortable setting. The treatment entails twice-a-week sessions for the first four weeks, followed by once-a-week sessions for a month, with the frequency adjusted according to the patient's response.

"Our mission at New Brain Institute is to provide innovative and effective treatments to individuals struggling with depression," said Dr. Emily Thompson, Founder and CEO of New Brain Institute. "We are excited to offer ketamine therapy using SPRAVATO™, as it has shown remarkable results in improving the lives of our patients."

The safety and effectiveness of SPRAVATO™ have been evaluated in both short- and long-term clinical trials. During treatment sessions, patients are closely monitored by healthcare professionals for a minimum of two hours. It is advised that patients refrain from driving or operating machinery until the following day.

A recent clinical study demonstrated that adults with treatment-resistant depression, who received SPRAVATO™ alongside an oral antidepressant, experienced significant reductions in depression symptoms compared to those who received a placebo. The treatment has been covered by many insurance plans, and New Brain Institute accepts most insurance options.

"We encourage patients who have not responded to at least two antidepressants to consider SPRAVATO™ as a potential life-changing treatment," said Dr. Thompson. "Depression can be debilitating, and it is important to explore all available options for those in need."

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

A cutting-edge technique known as Deep transcranial magnetic stimulation (Deep TMS) has been developed to alleviate post-traumatic stress disorder (PTSD) symptoms, among other neurological and neuropsychological disorders. PTSD is a mental illness experienced by those who have undergone stressful and traumatic events. Disturbing flashbacks mark it as negative changes in thinking and mood, emotional instability, hopelessness for the future, and other symptoms, which can be present for years if not addressed. Both adults and children can develop PTSD due to their exposure to critical incidences or life events.

New Brain Institute of Beverly Hills & Los Angeles County, and medical professionals globally have recognized Deep TMS’s potential as a remedy for PTSD. Deep TMS is beneficial for PTSD because it stimulates nerve cells in a patient's brain to alleviate the adverse effects of anxiety and depression, both of which are common symptoms of PTSD.

New Brain Institute believes that the latest development is a significant milestone in treating PTSD. Deep TMS is non-invasive, painless, and more effective than other treatments previously used for the condition. Patients have seen substantial relief in their symptoms with this therapy.

Deep TMS is a safe therapy method that uses magnetic pulses directed to the patient's brain, stimulating nerve cells in that area to resolve symptoms associated with PTSD. The treatment is novel, state-of-the-art, and painless, which involves no surgery, medications, or anesthesia. Deep TMS also has minimal side effects, without impairing a patient’s cognitive abilities or memory. Most importantly, the therapy is very well tolerated by patients, which makes it more effective in treating PTSD symptoms.

The therapy sessions and treatment frequency depend on the severity and assessment of each patient’s condition. Patients may start feeling the effects of the treatment after several sessions, and continued therapy provides a lasting benefit.

The Deep TMS technique is proving to be a significant milestone for patients suffering from PTSD. Medical professionals can now provide more effective, non-invasive treatments for neurological disorders, including PTSD, that enhance the overall quality of patient care.

About New Brain Institute

New Brain Institute can offer a new way to a happy, everyday life with Deep TMS, an effective, non-invasive depression treatment. Deep TMS can help you even if medications and psychotherapy have failed to do so. It is very effective even in patients who have tried multiple trials of medication and therapy to no avail.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.